Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
The publication presents a phase III clinical trial evaluating the efficacy and safety of a novel targeted therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring specific genetic mutations.
The study demonstrates a significant improvement in progression-free survival compared to standard chemotherapy, with a manageable safety profile.
These findings support the use of this targeted agent as a new standard of care for this patient subgroup.